Oncotarget

Research Papers:

Trisenox disrupts MDM2-DAXX-HAUSP complex and activates p53, cell cycle regulation and apoptosis in acute leukemia cells

Sanjay Kumar, Andrea Brown and Paul B. Tchounwou _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:33138-33148. https://doi.org/10.18632/oncotarget.26025

Metrics: PDF 677 views  |   HTML 1305 views  |   ?  


Abstract

Sanjay Kumar1, Andrea Brown1 and Paul B. Tchounwou1

1Cellomics and Toxicogenomics Research Laboratory, NIH/NIMHD-RCMI Center for Environmental Health, College of Science, Engineering and Technology, Jackson State University, Jackson, Mississippi, MS 39217, USA

Correspondence to:

Paul B. Tchounwou, email: paul.b.tchounwou@jsums.edu

Keywords: trisenox; APL; MDM2-DAXX-HAUSP complex; p53; apoptosis

Received: July 11, 2018     Accepted: August 13, 2018     Published: September 04, 2018

ABSTRACT

Trisenox (TX) has been used in the treatment of both de novo and relapsed acute promyelocytic leukemia (APL) patients. Using in vitro APL cell lines model in this research, we report on a new target of TX action through disruption of MDM2-DAXX-HAUSP complex, degradation of MDM2, and activation of p53 expression. TX–induced stress signal was transmitted by protein kinase (ATM & ATR) and phosphorylation of its downstream targets CHK1, CHK2, ATM, and ATR, respectively at the Ser 345, Thr68, Ser1981 and Ser 428 residues involved in complex disruption and p53 up-regulation. TX-activated p53 led to cell cycle arrest and apoptosis in APL cells. Our results showed that TX inhibited cell proliferation, disrupted complex molecules expression and association in APL cells. Our functional studies indicated that TX-induced down-regulation of complex molecules expression was mostly neutralized in both p53 knockdown NB4 cells and nutilin-3 treated KG1a cells. Hence our findings provide a functional evidence of TX action on cell cycle regulation and apoptosis in APL cells. This novel target of TX activity may be useful for designing new APL drugs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26025